The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...

On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics, whose share rose more than 8% to 44.03 on the news.

The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging ...

Geron Corporation has secured $375 million to support the US and potential EU launch of Rytelo and pipeline development. The ...

Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. A calculation from the Medical Council shows that out ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...

According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...